Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04856176 2025-01-01

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Phase 2 Terminated

5 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04364048 2024-12-20

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 10 charts

Thoracic

Lung Neoplasms

NCT01088906 2024-10-15

Phalcis

Phase 2 Terminated

57 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00998166 2024-07-30

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

Phase 2 Terminated

12 enrolled 3 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03840902 2024-01-16

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

153 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04422392 2023-08-30

Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

Phase 2 Terminated

93 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04971187 2023-08-01

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Phase 2 Terminated

3 enrolled 8 charts

Thoracic

Lung Neoplasms

NCT02710396 2023-07-24

Genetic Predictors of Benefit to Pembrolizumab

Phase 2 Terminated

19 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04372927 2023-06-13

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Phase 2 Terminated

1 enrolled 10 charts

Thoracic

Lung Neoplasms

NCT03838848 2023-03-02

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03713944 2023-03-01

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

30 enrolled 28 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04265534 2022-09-21

KEAPSAKE

Phase 2 Terminated

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00754364 2022-09-10

Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients

Phase 2 Terminated

108 enrolled

Thoracic

NSCLC

NCT00394147 2022-08-05

Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer

Phase 2 Terminated

17 enrolled 8 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms

NCT03041181 2022-07-11

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Phase 2 Terminated

3 enrolled 11 charts

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT00402883 2021-11-09

Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

Phase 2 Terminated

5 enrolled 6 charts

Thoracic

Lung Neoplasms

NCT02693717 2021-05-20

Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer

Phase 2 Terminated

7 enrolled 5 charts

Genitourinary

Carcinoma, Transitional Cell

NCT00438204 2021-04-13

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Terminated

39 enrolled 9 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03256721 2021-02-08

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Phase 2 Terminated

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00538681 2020-11-05

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Phase 2 Terminated

35 enrolled 14 charts

Thoracic

Lung Neoplasms

NCT00859495 2020-08-25

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

Phase 2 Terminated

9 enrolled 4 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02624700 2020-07-14

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Phase 2 Terminated

13 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02357147 2020-03-17

ARTEMIS

Phase 2 Terminated

124 enrolled 10 charts

Other solid neoplasmThoracic

Severe combined immunodeficiency with sensitivity to ionizing radiation, Mesothelioma, Malignant

NCT02134912 2020-02-20

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Phase 2 Terminated

1 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT02117024 2020-02-05

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Phase 2 Terminated

66 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02200354 2019-08-14

The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

Phase 2 Terminated

20 enrolled

Thoracic

Advanced Non-small Cell Lung Cancer

NCT01646125 2019-07-24

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Phase 2 Terminated

59 enrolled 9 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02595840 2019-04-19

Trans-MARBLE

Phase 2 Terminated

4 enrolled

Thoracic

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Tumor-Agnostic

Neoplasms

NCT00769600 2019-02-01

Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC

Phase 2 Terminated

23 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01935947 2018-07-27

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

17 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00096187 2018-04-12

Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy

Phase 2 Terminated

55 enrolled

Gynecologic

Gestational Trophoblastic Disease

NCT02119650 2018-02-13

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Phase 2 Terminated

76 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01860040 2018-02-07

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Phase 2 Terminated

1 enrolled 5 charts

Thoracic

Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer

NCT02919462 2018-01-16

HighTySy

Phase 2 Terminated

2 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02488694 2018-01-09

MARBLE

Phase 2 Terminated

4 enrolled

Thoracic

Non-small-cell Lung Cancer With Somatic EGFR Mutations

Clinical Trials

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

BRIDGE

Pembro+Chemo in Brain Mets

CARMEN-LC05

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Phalcis

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Genetic Predictors of Benefit to Pembrolizumab

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

KEAPSAKE

Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients

Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

ARTEMIS

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Trans-MARBLE

GSK1120212 Rollover Study

Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

HighTySy

MARBLE